Literature DB >> 27330421

Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.

Vittoria Colia1, Salvatore Provenzano1, Nadia Hindi1, Paolo G Casali1, Silvia Stacchiotti1.   

Abstract

This review highlights the data currently available on the activity of systemic therapy in chondrosarcoma, chordoma, giant cell tumour of the bone (GCTB) and solitary fibrous tumour, i.e., four rare sarcomas amongst mesenchymal malignancy arising from the skull base.

Entities:  

Keywords:  Chondrosarcoma; Chordoma; Giant cell tumour; Sarcoma; Skull base; Solitary fibrous tumour

Year:  2016        PMID： 27330421      PMCID： PMC4899415          DOI： 10.1016/j.rpor.2015.12.005

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN： 1507-1367


  65 in total

1.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

2.  Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases.

Authors:  Feng Wei; Xiaoguang Liu; Zhongjun Liu; Liang Jiang; Gengting Dang; Qingjun Ma; Lei Dang
Journal:  Spine (Phila Pa 1976)       Date:  2010-11-15       Impact factor: 3.468

3.  Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: 
Journal:  Ann Oncol       Date:  2014-09       Impact factor: 32.976

4.  Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study.

Authors:  Anna Maria Frezza; Marilena Cesari; Daniel Baumhoer; David Biau; Stephen Bielack; Domenico Andrea Campanacci; José Casanova; Claire Esler; Stefano Ferrari; Philipp T Funovics; Craig Gerrand; Robert Grimer; Alessandro Gronchi; Nicolas Haffner; Stefanie Hecker-Nolting; Sylvia Höller; Lee Jeys; Paul Jutte; Andreas Leithner; Mikel San-Julian; Joachim Thorkildsen; Bruno Vincenzi; Reinhard Windhager; Jeremy Whelan
Journal:  Eur J Cancer       Date:  2014-12-16       Impact factor: 9.162

5.  Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy.

Authors:  George R Matcuk; Dakshesh B Patel; Aaron J Schein; Eric A White; Lawrence R Menendez
Journal:  Skeletal Radiol       Date:  2015-02-26       Impact factor: 2.199

6.  Advanced chondrosarcomas: role of chemotherapy and survival.

Authors:  A Italiano; O Mir; A Cioffi; E Palmerini; S Piperno-Neumann; C Perrin; L Chaigneau; N Penel; F Duffaud; J E Kurtz; O Collard; F Bertucci; E Bompas; A Le Cesne; R G Maki; I Ray Coquard; J Y Blay
Journal:  Ann Oncol       Date:  2013-10-07       Impact factor: 32.976

7.  Imatinib mesylate in chordoma.

Authors:  Paolo G Casali; Antonella Messina; Silvia Stacchiotti; Elena Tamborini; Flavio Crippa; Alessandro Gronchi; Rosaria Orlandi; Carla Ripamonti; Carlo Spreafico; Raffaello Bertieri; Rossella Bertulli; Maurizio Colecchia; Elena Fumagalli; Angela Greco; Federica Grosso; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

Review 8.  Skull base chondrosarcoma: evidence-based treatment paradigms.

Authors:  Orin Bloch; Andrew T Parsa
Journal:  Neurosurg Clin N Am       Date:  2013-01       Impact factor: 2.509

9.  GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study.

Authors:  A Italiano; A Le Cesne; C Bellera; S Piperno-Neumann; F Duffaud; N Penel; P Cassier; J Domont; N Takebe; M Kind; J-M Coindre; J-Y Blay; B Bui
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976

10.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.

Authors:  P G Casali; P Bruzzi; J Bogaerts; J-Y Blay
Journal:  Ann Oncol       Date:  2014-10-01       Impact factor: 32.976
View more
  7 in total

1.  Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system.

Authors:  Connor J Kinslow; Raj S Rajpara; Cheng-Chia Wu; Samuel S Bruce; Peter D Canoll; Shih-Hsiu Wang; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Tony J C Wang
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

Review 2.  Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).

Authors: 
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

3.  Cyberknife stereotactic radiosurgery and denosumab for giant cell tumour of the skull base: Case report.

Authors:  Cuauhtemoc de la Peña; Jorge H Guajardo; Maria F Gonzalez; Miguel A Hinojosa; Erick Cardona
Journal:  Rep Pract Oncol Radiother       Date:  2017-08-30

4.  Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review.

Authors:  Vittoria Colia; Salvatore Provenzano; Carlo Morosi; Paola Collini; Salvatore Lorenzo Renne; Paolo G Dagrada; Claudia Sangalli; Angelo Paolo Dei Tos; Andrea Marrari; Paolo G Casali; Silvia Stacchiotti
Journal:  Clin Sarcoma Res       Date:  2016-09-01

5.  Locally advanced malignant solitary fibrous tumour successfully treated with conversion chemotherapy, operation and postoperative radiotherapy: a case report.

Authors:  Zhi-Ke Li; Jie Liu; Chen Chen; Ke-Yi Yang; Yao-Tiao Deng; Yu Jiang
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

6.  Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab.

Authors:  A Deodati; D Fintini; E Levtchenko; M Rossi; G Ubertini; H Segers; G Battafarano; M Cappa; A Del Fattore
Journal:  J Endocrinol Invest       Date:  2021-07-03       Impact factor: 4.256

7.  High LET Radiation Overcomes In Vitro Resistance to X-Rays of Chondrosarcoma Cell Lines.

Authors:  Francois Chevalier; Dounia Houria Hamdi; Charlotte Lepleux; Mihaela Temelie; Anaïs Nicol; Jean Baptiste Austry; Paul Lesueur; Guillaume Vares; Diana Savu; Tetsuo Nakajima; Yannick Saintigny
Journal:  Technol Cancer Res Treat       Date:  2019-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.